In this study, selective induction of Gal-9, but not of other galectins, was also observed in vitro across a broad panel of EGFR-wild-type and mutant human and murine NSCLC, lung, and colon cancer cells treated with the EGFR-TKIs, osimertinib, erlotinib, gefitinib, or afatinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.